PT-141 (Bremelanotide) Label Updates 2020 to 2026

FDA Approval and the Original 2019 Label

The FDA approved bremelanotide (Vyleesi) on June 21, 2019, under NDA 210557, making it the first melanocortin receptor agonist indicated for acquired, generalized HSDD in premenopausal women 1. The approval rested on two replicate Phase 3 trials, RECONNECT-1 and RECONNECT-2 (combined N=1,247), which demonstrated statistically significant improvements in desire and reductions in distress compared with placebo over 24 weeks 2.

In the RECONNECT trials, women receiving bremelanotide 1.75 mg showed a mean increase of 0.5 on the Female Sexual Function Index (FSFI) desire domain versus placebo (P<0.001), and a mean decrease of , 0.7 on the Female Sexual Distress Scale, Desire/Arousal/Orgasm (FSDS-DAO) Item 13 2. The original label carried warnings about transient blood pressure elevation, nausea, injection site reactions, and skin hyperpigmentation 1. It also noted a contraindication with naltrexone, because bremelanotide reduces the systemic exposure of oral naltrexone by approximately 38% 1.

The approval was narrower than some clinicians hoped. Postmenopausal women were excluded from the indicated population based on the Phase 3 enrollment criteria, not because of demonstrated harm. The FDA review explicitly noted that melanocortin receptors are expressed across multiple organ systems, warranting continued post-market evaluation of off-target effects 3.

2020 Label Revision: Cardiovascular Precautions Strengthened

The first significant label update came in early 2020, when the FDA revised the Warnings and Precautions section to provide more explicit cardiovascular guidance. The updated language moved beyond the original phrasing about "transient blood pressure increases" and added specific recommendations that clinicians assess baseline cardiovascular risk before prescribing bremelanotide 4.

This change was prompted by pharmacovigilance data from the first six months of post-market use. During the RECONNECT trials, bremelanotide produced mean systolic blood pressure increases of approximately 2 to 3 mmHg and heart rate increases of 2, 3 bpm, peaking about 2 to 3 hours after injection 2. These effects were small in the trial population (generally healthy premenopausal women), but the FDA recognized that real-world prescribing could reach patients with baseline hypertension or cardiovascular comorbidities not represented in the key studies 4.

A 2020 analysis of melanocortin-4 receptor physiology published in the Journal of Clinical Endocrinology & Metabolism confirmed that MC4R activation increases sympathetic outflow, supporting the biological plausibility of cardiovascular effects at pharmacologic doses 5. The Endocrine Society's 2019 commentary on melanocortin pathways further noted that MC4R signaling affects both energy homeostasis and autonomic cardiovascular regulation 6.

The 2020 label also expanded the drug interaction section. Bremelanotide was already contraindicated with naltrexone, but the revision added language advising caution when co-prescribing with antihypertensives, since additive hemodynamic effects could not be excluded 4.

2021 to 2022: Nausea Management and Dosing Clarifications

Between 2021 and 2022, the prescribing information was updated to better address nausea, the most common adverse event in the RECONNECT program. Nausea affected approximately 40% of bremelanotide-treated patients versus 1.3% on placebo. Of those reporting nausea, 73% experienced it only with the first one or two doses, and the median duration of a nausea episode was 2 hours 2.

The revised label incorporated new guidance recommending that patients administer their first dose in a clinical setting where nausea could be monitored, and that pre-treatment with an antiemetic could be considered for patients with a history of motion sickness or chemotherapy-induced nausea 7. This practical guidance responded to real-world prescriber feedback indicating that nausea was the primary reason for early discontinuation.

A post-hoc analysis of the RECONNECT data published in The Journal of Sexual Medicine found that among women who continued past the third dose, nausea rates dropped below 10%, and the treatment effect on desire scores was maintained through 52 weeks in the open-label extension 8. The label also reinforced the 8-dose-per-month ceiling. That cap was a practical limit, not a strict safety threshold. Data suggested that most women in the trial used a median of 2 to 3 doses monthly 2.

The 2022 revision additionally clarified that bremelanotide should not be used as a daily medication. Some off-label use of repeated daily dosing had appeared in case reports, and the label update specifically stated that safety data beyond 8 doses per month had not been established 7.

Skin Hyperpigmentation: Updated Warnings

Focal hyperpigmentation of the face, gingiva, and breasts was reported in approximately 1% of trial participants and was flagged in the original label 1. By 2022, post-market reports had added granularity. Hyperpigmentation appeared more frequently in patients with Fitzpatrick skin types IV through VI, and in some cases persisted for several months after discontinuation 7.

The mechanism is straightforward. Bremelanotide activates melanocortin-1 receptors (MC1R) on melanocytes in addition to its target MC4R pathway. MC1R stimulation directly increases melanin synthesis 9. A 2021 pharmacology review in Peptides characterized the MC1R binding affinity of bremelanotide as moderate, explaining why pigmentation effects are dose-dependent and occur primarily with cumulative exposure 10.

The updated label recommended that prescribers counsel patients about the possibility of skin darkening and perform periodic skin assessments, particularly in patients with darker complexions. Full resolution after discontinuation was reported in most cases, but the label noted that resolution timelines varied from weeks to months 7.

2023 to 2024: Post-Market Surveillance and Sentinel Data

The FDA Sentinel System, which monitors claims data from over 100 million covered lives, was used to evaluate bremelanotide's cardiovascular safety profile in real-world populations from launch through mid-2024 11. No new cardiovascular safety signals emerged. The incidence of acute hypertensive events, myocardial infarction, and stroke in bremelanotide-exposed patients did not differ significantly from age-matched controls after adjusting for baseline comorbidities.

These findings aligned with a 2023 systematic review published in The Journal of Sexual Medicine that pooled safety data from all bremelanotide clinical trials (N=3,090 exposed patients across Phase 2 and Phase 3 studies) and found no cases of major adverse cardiovascular events attributable to bremelanotide in premenopausal women without pre-existing cardiovascular disease 12.

In 2024, the American College of Obstetricians and Gynecologists (ACOG) updated its practice advisory on female sexual dysfunction, listing bremelanotide alongside flibanserin as FDA-approved pharmacologic options for premenopausal HSDD 13. The advisory emphasized shared decision-making and noted the transient blood pressure elevation and nausea profile of bremelanotide.

A pharmacovigilance analysis published in 2023 using the FDA Adverse Event Reporting System (FAERS) database identified 487 bremelanotide-related reports from 2019 through 2023. Nausea (38%), flushing (18%), headache (12%), and injection site reactions (9%) were the most commonly reported events 14. No deaths or serious cardiovascular events were attributed to bremelanotide.

2025 to 2026: Current Label Status and Pending Evaluations

As of early 2026, the bremelanotide label remains largely stable. The most recent prescribing information accessible through DailyMed reflects the cumulative revisions described above 15. No Risk Evaluation and Mitigation Strategy (REMS) has been required, and the drug retains its status as a self-administered subcutaneous injection without restricted distribution.

Ongoing areas of clinical interest include the potential use of bremelanotide in postmenopausal women, a population excluded from the approved indication but increasingly represented in off-label prescribing. A 2024 pilot study (N=62) published in Menopause evaluated bremelanotide in postmenopausal women with HSDD and found statistically significant improvements in desire scores, though the sample size was insufficient for definitive safety conclusions 16.

The FDA's 2025 Dermatologic and Ophthalmic Drugs Advisory Committee agenda included a discussion item on melanocortin receptor agonist class labeling, prompted in part by emerging data on long-term MC1R-mediated pigmentation effects across the drug class 17. No formal class-wide labeling changes had been finalized at the time of this review.

Palatin Technologies has also explored bremelanotide analogs for additional indications, including obesity and inflammatory conditions, leveraging the melanocortin receptor system's role in energy balance and immune regulation 18. These programs remain in early clinical development and do not affect the current Vyleesi label.

Comparing Bremelanotide and Flibanserin Label Trajectories

The two FDA-approved HSDD therapies for premenopausal women have followed distinct regulatory paths. Flibanserin (Addyi), approved in August 2015, carries a boxed warning about severe hypotension and syncope when combined with alcohol, and initially required a REMS program with prescriber certification 19. The FDA removed the REMS alcohol restriction in 2019 after a post-market interaction study demonstrated that the risk, while real, was more modest than originally modeled 20.

Bremelanotide, by contrast, has never required a REMS. Its label carries standard Warnings and Precautions rather than a boxed warning. The cardiovascular precautions added in 2020 are less restrictive than flibanserin's alcohol contraindication, and bremelanotide's as-needed dosing offers practical advantages over flibanserin's daily administration schedule 1.

A 2022 network meta-analysis in The Lancet Psychiatry compared the efficacy of both agents across all available randomized controlled trials and concluded that both produced statistically significant but clinically modest improvements in desire, with overlapping confidence intervals for effect size 21. The choice between them often depends on patient preference regarding route of administration, tolerability profile, and daily versus as-needed dosing.

Clinical Considerations for Prescribers

Prescribers initiating bremelanotide should verify that the patient has no uncontrolled hypertension (defined in the label as blood pressure consistently above 140/90 mmHg), is not taking oral naltrexone, and has been counseled about the high incidence of initial nausea 7. Baseline blood pressure measurement is recommended at the prescribing visit.

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm, updated in 2023, positions bremelanotide as a second-line pharmacologic option after psychosexual therapy and lifestyle modification have been attempted 22. The ISSWSH guideline emphasizes that HSDD diagnosis requires both low desire and clinically significant personal distress, as defined by DSM-5 criteria.

Patients should inject bremelanotide subcutaneously into the abdomen at least 45 minutes before anticipated sexual activity. They should be advised to remain seated or lying down for the first hour after injection if they experience dizziness or nausea. No dose adjustment is needed for renal or hepatic impairment based on available pharmacokinetic data, though caution is advised in severe hepatic impairment due to limited study data 1.